FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug

BeiGene and Novartis will have to wait a little longer for a potential regulatory review of their checkpoint inhibitor, tislelizumab, as a potential second-line treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC).